GlassScriptPhysician profile
Olivia Marlowe
NPI 1205404514
$5,594.07
in general payments reported to CMS, 2019-2025
38 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $272 · 2024: $4,943 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,368.67 |
| Education | $225.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $986.94 | 2023-2024 | Nayzilam, Briviact, Rystiggo |
| Abbvie INC. | $356.12 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $293.09 | 2024 | |
| Alexion Pharmaceuticals, INC. | $289.27 | 2023-2024 | Ultomiris, Soliris |
| Biogen, INC. | $287.95 | 2023-2024 | Vumerity, Tysabri, Plegridy |
| Ani Pharmaceuticals, INC. | $251.11 | 2024 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $246.45 | 2023-2024 | Austedo Xr, Ajovy |
| Pfizer INC. | $225.32 | 2024 | |
| Lilly USA, LLC | $210.23 | 2023-2024 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $208.97 | 2024 | |
| Jazz Pharmaceuticals INC. | $207.15 | 2023-2024 | |
| Harmony Biosciences LLC | $197.96 | 2024 | |
| Neurocrine Biosciences, INC. | $175.34 | 2023-2024 | Ingrezza |
| Neurelis, INC. | $154.50 | 2024 | Valtoco |
| Emd Serono, INC. | $141.40 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $141.16 | 2024 | |
| Smith+Nephew, INC. | $128.58 | 2025 | "Acticoat 4"" X 4""", Collagenase Santyl, Biobrane |
| Vertex Pharmaceuticals Incorporated | $116.63 | 2025 | |
| Genzyme Corporation | $115.86 | 2025 | |
| Inspire Medical Systems, INC. | $87.47 | 2024 | Inspire |
| Eisai INC. | $73.70 | 2023-2024 | |
| Celgene Corporation | $69.16 | 2024 | Zeposia |
| Acadia Pharmaceuticals INC | $61.60 | 2024 | Nuplazid |
| Grifols USA, LLC | $58.23 | 2024 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $57.85 | 2024 | |
| Kyowa Kirin, INC. | $55.08 | 2024 | Nourianz |
| Axsome Therapeutics, INC. | $54.35 | 2023-2024 | Sunosi |
| Lundbeck LLC | $48.30 | 2024 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $47.48 | 2024 | Rexulti, Nuedexta |
| Tanabe Pharma America, INC. | $47.10 | 2024 | |
| Banner Life Sciences, LLC | $46.16 | 2024 | |
| Alnylam Pharmaceuticals INC. | $45.75 | 2024 | Onpattro |
| Revance Therapeutics, INC. | $26.51 | 2024 | Daxxify |
| Amgen INC. | $20.27 | 2024 | Uplizna |
| Cycle Pharmaceuticals INC | $16.47 | 2024 | Tascenso Odt |
| Ipsen Biopharmaceuticals, INC | $15.63 | 2024 | Dysport |
| Sumitomo Pharma America, INC. | $15.14 | 2024 | Aptiom |
| Mdd US Operations, LLC | $13.79 | 2024 | Apokyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Marlowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.